SCHEMBL8401736

SCHEMBL8401736

Nc1n[nH]c2cncc(-c3ccc4sc5ccccc5c4c3)c12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 3/20 0.48
▸ KDR P35968 10/20 0.44
▸ LCK P06239 4/20 0.44
▸ CSF1R P07333 4/20 0.44
▸ KIT P10721 3/20 0.44
▸ FLT3 P36888 3/20 0.44
▸ LYN P07948 3/20 0.44
▸ SRC P12931 3/20 0.44
▸ FLT1 P17948 3/20 0.44
▸ BLK P51451 3/20 0.44
▸ FYN P06241 2/20 0.44
▸ FLT4 P35916 2/20 0.44
▸ ABL1 P00519 2/20 0.44
▸ JAK2 O60674 5/20 0.42
▸ JAK1 P23458 1/20 0.42
▸ TYK2 P29597 1/20 0.42
▸ JAK3 P52333 1/20 0.42
▸ PDGFRB P09619 3/20 0.41
▸ PDPK1 O15530 3/20 0.38
▸ KDM4E B2RXH2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8401672 0.77 BTK (0.57) BTKKDRLCKCSF1RKIT
SCHEMBL5555113 0.76 JAK2 (0.55) BTKKDRLCKCSF1RKIT
SCHEMBL1703256 0.73 BTK (0.67) BTKKDRLCKCSF1RKIT
SCHEMBL6115425 0.71 BTK (0.67) BTKKDRLCKCSF1RKIT
SCHEMBL8401763 0.71 BTK (0.56) BTKKDRLCKCSF1RKIT
SCHEMBL6116270 0.70 BTK (0.55) BTKKDRLCKCSF1RKIT
SCHEMBL10029293 0.70 GPR3 (0.50) KDRKDM4E
SCHEMBL21283018 0.69 GPR3 (0.58) KDM4E
SCHEMBL6116082 0.69 BTK (0.52) BTKKDRLCKCSF1RKIT
SCHEMBL6116012 0.69 BTK (0.57) BTKKDRLCKCSF1RKIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2789615-A1 Azaindazoles as Btk kinase modulators and use thereof Bristol-Myers Squibb Company (US) 2014-10-15 — — EP claimed
US-8846673-B2 Azaindazoles as kinase inhibitors and use thereof BRISTOL-MYERS SQUIBB COMPANY (US) 2014-09-30 — — US claimed
EP-2789615-A1 Azaindazoles as Btk kinase modulators and use thereof Bristol-Myers Squibb Company (US) 2014-10-15 — — EP disclosed
EP-2789615-A1 Azaindazoles as Btk kinase modulators and use thereof Bristol-Myers Squibb Company (US) 2014-10-15 — — EP disclosed
US-8846673-B2 Azaindazoles as kinase inhibitors and use thereof BRISTOL-MYERS SQUIBB COMPANY (US) 2014-09-30 — — US disclosed
US-8846673-B2 Azaindazoles as kinase inhibitors and use thereof BRISTOL-MYERS SQUIBB COMPANY (US) 2014-09-30 — — US disclosed
US-20120129852-A1 AZAINDAZOLES AS KINASE INHIBITORS AND USE THEREOF BRISTOL-MYERS SQUIBB COMPANY 2012-05-24 — — US disclosed
US-20120129852-A1 AZAINDAZOLES AS KINASE INHIBITORS AND USE THEREOF BRISTOL-MYERS SQUIBB COMPANY 2012-05-24 — — US disclosed
WO-2011019780-A1 AZAINDAZOLES AS BTK KINASE MODULATORS AND USE THEREOF BRISTOL-MYERS SQUIBB COMPANY (US) 2011-02-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120129852-A1 AZAINDAZOLES AS KINASE INHIBITORS AND USE THEREOF BTK, ABL1, JAK1 BTK 1/4885KDR 476/4885LCK 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback